| ★ | Abdominal Pain and Bloating: Recognizing HAE, MCAS, and Eosinophilic GI Disorders | Brian Lacy, MD | | 20 | Estados Unidos | |
| 19 | Furoscix ReadyFlow (Furosemide) and its Impact on HF, CKD Edema Treatment | | 374 | Estados Unidos | 67 |
| 14 | Inhaled Treprostinil for IPF: TETON-1 Phase 3 Results With Steven Nathan, MD | ATS 2026 | | 301 | Estados Unidos | 68 |
| 7 | COMP360 Psilocybin's 26-Week Data in Treatment-Resistant Depression I Boadie Dunlop, MD | | 178 | Estados Unidos | 69 |
| 3 | All 12 Tegoprubart Recipients Off External Insulin Following Islet Implant in Pilot Study | | 168 | Estados Unidos | 71 |
| 17 | Highlighting FDA-Approved Therapies in Atopic Dermatitis, With Chris Bunick, MD, PhD | | 152 | Estados Unidos | 67 |
| 13 | New Martin-Hopkins LDL-C-Estimating Equation Simplifies Implementation for Comparable Results | | 151 | Estados Unidos | 68 |
| 9 | FIND-CKD Trial Poses Finerenone as a "Third Pillar" for Nondiabetic CKD | | 123 | Estados Unidos | 69 |
| 8 | Total Plaque Volume Indicates Patients With 0 CAC May Still be at Risk | | 120 | Estados Unidos | 69 |
| 6 | Phase 3b ENCORE: ALIS Improves MAC Lung Disease Outcomes | ATS 2026 | | 117 | Estados Unidos | 70 |
| 15 | SYMPHONY-PE: Early Thrombectomy Improves Pulmonary Embolism Outcomes | | 86 | Estados Unidos | 68 |
| 16 | ZUPREME-1: Petrelintide Reduces Obesity, Maintains Tolerability in Phase 2 Trial | | 81 | Estados Unidos | 68 |
| 12 | Omalizumab vs Oral Immunotherapy for Multifood Allergy | | 65 | Estados Unidos | 69 |
| 4 | Addressing Advances and Roadblocks in Lipid Management, With Joseph Saseen, PharmD | | 64 | Estados Unidos | 70 |
| 18 | How Well-Being in Psoriasis is Being Assessed Via WHO-5, With Ulrich Mrowietz, MD | | 56 | Estados Unidos | 67 |
| 10 | Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH | | 46 | Estados Unidos | 69 |
| 11 | FMD Peak Systolic Velocity May Lead to Comprehensive Clinical Guidelines | | 33 | Estados Unidos | 69 |
| 1 | Diagnosing Non-IgE Food Hypersensitivity | Brian Lacy, MD, PhD | EAC 2026 | | 31 | Estados Unidos | 75 |
| 5 | Sebetralstat & Quality of Life in Breakthrough HAE | Daniel Soteres, MD | | 29 | Estados Unidos | 70 |
| 2 | Addressing the Manifold Barriers in Hypertension, With Michael Miedema, MD | | 27 | Estados Unidos | 72 |
| 20 | How ABCG2 Inhibition Could Change EPP Disease Management | | 17 | Estados Unidos | 67 |